(NP (NP Increased/VBN interleukin/NN 2/CD transcription/NN) (PP in/IN (NP murine/JJ lymphocytes/NNS)) (PP by/IN (NP ciprofloxacin/NN)) ./.)
(S (NP-SBJ (NP The/DT fluoroquinolone/JJ antibiotic/JJ) ,/, (NP (NP ciprofloxacin/NN) (PRN -LRB-/-LRB- (NP cipro/NN) -RRB-/-RRB-)) ,/,) (VP induces/VBZ (NP (NP hyperproduction/NN) (PP of/IN (NP-COOD (NP (NP interleukin/NN 2/CD) (PRN -LRB-/-LRB- (NP IL-2/NN) -RRB-/-RRB-)) and/CC (NP (NP interferon-gamma/NN) (PRN -LRB-/-LRB- (NP IFN-gamma/NN) -RRB-/-RRB-)))) (PP in/IN (NP stimulated/VBN human/JJ peripheral/JJ blood/NN lymphocytes/NNS)))) ./.)
(S (PP In/IN (NP this/DT investigation/NN)) (NP-SBJ-1 an/DT (ADJP-COOD (ADJP enhanced/VBN) and/CC (ADJP prolonged/JJ)) (NP-COOD (NP IL-2/NN) and/CC (NP IL-2/NN mRNA/NN)) response/NN) (VP was/VBD (VP (ADVP also/RB) detected/VBN (NP *-1/-NONE-) (PP-COOD (PP in/IN both/CC (NP (ADJP (NP *ICH*-2/-NONE-) stimulated/VBN -LRB-/-LRB- (NP-2 T/NN cell/NN (NP-COOD (NP mitogens/NNS) or/CC (NP alloantigens/NNS))) -RRB-/-RRB-) murine/JJ splenocytes/NNS)) and/CC (PP in/IN (NP the/DT stimulated/VBN murine/JJ T/NN cell/NN line/NN EL-4/NN))) (PP in/IN the/DT presence/NN of/IN (NP (NP ciprofloxacin/NN) (PRN -LRB-/-LRB- (NP (QP 5-80/CD) micrograms\/ml/NN) -RRB-/-RRB-))) (SBAR as/IN (S (NP-SBJ-6 */-NONE-) (VP compared/VBN (NP *-6/-NONE-) (PP to/TO (NP (NP control/NN cells/NNS) (PP without/IN (NP antibiotics/NNS))))))))) ./.)
(S (ADVP However/RB) ,/, (PP in/IN contrast/NN to/TO (NP human/JJ lymphocytes/NNS)) ,/, (S-COOD (S (NP-SBJ-3 IFN-gamma/NN production/NN) (VP was/VBD (VP inhibited/VBN (NP *-3/-NONE-)))) and/CC (S (NP-SBJ-4 IFN-gamma/NN mRNA/NN levels/NNS) (VP were/VBD (VP (VP-COOD (VP unaffected/JJ (NP *-4/-NONE-) (PP-TMP at/IN (NP (NP 24/CD h/NN) (PP *RNR*-101/-NONE-)))) and/CC (VP (ADVP only/RB slightly/RB) upregulated/VBN (NP *-4/-NONE-) (PP-TMP at/IN (NP (NP (QP 48/CD and/CC 72/CD) h/NN) (PP *RNR*-101/-NONE-))))) (PP-101 of/IN (NP culture/NN)) (PP in/IN (NP (NP murine/JJ splenocytes/NNS) (VP incubated/VBN (NP */-NONE-) (PP with/IN (NP (NP cipro/NN) (PRN -LRB-/-LRB- (NP 20/CD micrograms\/ml/NNS) -RRB-/-RRB-)))))))))) ./.)
(S (NP-SBJ-5 EL-4/NN cells/NNS) (VP were/VBD (VP transfected/VBN (NP *-5/-NONE-) (PP with/IN (NP (NP a/DT plasmid/NN) (VP containing/VBG (NP (NP the/DT IL-2/NN (NP-COOD (NP promoter/NN) and/CC (NP enhancer/NN)) region/NN) (VP linked/VBN (NP */-NONE-) (PP to/TO (NP the/DT (NP (NP chloramphenicol/NN acetyltransferase/NN) (PRN -LRB-/-LRB- (NP CAT/NN) -RRB-/-RRB-)) reporter/NN gene/NN))))))))) ./.)
(S (NP-SBJ (NP Analysis/NN) (PP of/IN (NP CAT/NN activity/NN))) (VP revealed/VBD (SBAR that/IN (S (NP-SBJ cipro/NN) (VP enhanced/VBD (NP IL-2/NN gene/NN induction/NN))))) ./.)
(S (PP In/IN (NP addition/NN)) ,/, (NP-SBJ-7 (NP EL-4/NN cells/NNS) (VP incubated/VBN (NP */-NONE-) (PP with/IN (NP ciprofloxacin/NN)))) (VP showed/VBD (NP-COOD (NP an/DT early/JJ peak/NN) and/CC (NP (ADJP more/RBR activated/VBN) (NP (NP (NP nuclear/JJ factor/NN) (PP of/IN (NP activated/VBN T/NN cells/NNS))) (PRN -LRB-/-LRB- (NP NFAT-1/NN) -RRB-/-RRB-)))) (SBAR as/IN (S (NP-SBJ-8 *-7/-NONE-) (VP compared/VBN (NP *-8/-NONE-) (PP to/TO (NP (NP control/NN cells/NNS) (PP without/IN (NP antibiotics/NNS)))))))) ./.)
(S (NP-SBJ Cipro/NN) (VP did/VBD not/RB (VP affect/VB (NP the/DT nuclear/JJ transcription/NN factors/NNS (NP-COOD (NP AP-1/NN) or/CC (NP NFIL-2A/NN))))) ./.)
(S (S (NP-SBJ-9 */-NONE-) (VP Taken/VBN (NP *-9/-NONE-) (ADVP together/RB))) ,/, (NP-SBJ-10 cipro/NN) (VP-COOD (VP inhibited/VBD (NP IFN-gamma/NN synthesis/NN)) ,/, but/CC (VP enhanced/VBD (NP (NP IL-2/NN production/NN) (PP in/IN (NP murine/JJ lymphocytes/NNS))) (PP by/IN means/NNS of/IN (S (NP-SBJ *-10/-NONE-) (VP-COOD (VP influencing/VBG (NP NFAT-1/NN)) and/CC (VP causing/VBG (NP an/DT increased/VBN IL-2/NN transcription/NN))))))) ./.)
